Bionano net loss widens 8.26% to $7.42 million in Q2 FY26; revenue rises 21% to $8.2 million
Reuters2026/08/10 20:12- Bionano Genomics reported Q2 revenue of USD 8.2 million, up 21% year over year, as consumables rose 31% to USD 4.3 million.
- Net loss widened to USD 7.42 million, while gross margin edged up 1 percentage point to 53%.
- Flow-cell volume climbed 27% to 9,219, while operating expenses increased 2% to USD 11.5 million.
- Management cited accelerating global adoption of optical genome mapping, driven mainly by increased clinical adoption and higher utilization at clinical sites.
- Issued Q3 revenue guidance of USD 8.2 million-USD 8.6 million, maintaining full-year guidance of USD 31 million-USD 33 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
At a sensitive moment of the "bond market storm," the market focuses on today's 30-year Japanese government bond auction.
Japan’s 30-year government bond yield has risen to 4.155%, approaching a historic high. The 30-year bond auction scheduled for Thursday is drawing significant attention. Analysts generally expect a weak result and warn that if the auction goes poorly, it could put reverse pressure on US Treasuries, prompting a repricing of the global fixed income market and potentially becoming a new trigger for rising global borrowing costs.
US President Donald Trump: Renewed campaign against Iran will not continue for too long
Yen: Intervention is a cycle
DOJ Antitrust Unit Adds Eight Retailers to Beef Pricing Investigation
Crypto prices
More
